FDA Grants Approval for Sugammadex Sodium ANDA214319 by Sun Pharma
The FDA has granted approval for Sugammadex Sodium under application ANDA214319 submitted by Sun Pharma.
| Drug | MOA / Company | Stage |
|---|---|---|
| Sugammadex | Sun Pharma | Lead |
Focal Asset
Sugammadex
Company
Sun Pharma
Indication
Anesthesia / Neuromuscular Blockade
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of Sugammadex Sodium by Sun Pharma introduces a new competitor in the neuromuscular blockade reversal market. This development necessitates a reassessment of pricing and market strategies for existing products in this therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market launch timelines and any subsequent competitive responses from other manufacturers.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.